Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Thalidomide and its derivatives, lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of haematologic malignancies. IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4(CRBN)) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous CRL4(CRBN) substrates. Unexpectedly, IMiDs also repurpose the ligase to target new proteins for degradation. Lenalidomide induces degradation of the lymphoid transcription factors Ikaros and Aiolos (also known as IKZF1 and IKZF3), and casein kinase 1α (CK1α), which contributes to its clinical efficacy in the treatment of multiple myeloma and 5q-deletion associated myelodysplastic syndrome (del(5q) MDS), respectively. How lenalidomide alters the specificity of the ligase to degrade these proteins remains elusive. Here we present the 2.45 Å crystal structure of DDB1-CRBN bound to lenalidomide and CK1α. CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop located in the kinase N-lobe. We show that CK1α binding to CRL4(CRBN) is strictly dependent on the presence of an IMiD. Binding of IKZF1 to CRBN similarly requires the compound and both, IKZF1 and CK1α, use a related binding mode. Our study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy. We anticipate that high-affinity protein-protein interactions induced by small molecules will provide opportunities for drug development, particularly for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [11]
In the citing paper
“This behaviour is reminiscent of CRL4CRBN and thalidomide analogues11,26, where an apparent affinity threshold must be overcome to drive drug-induced target degradation.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [11]
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [6]
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [6]
In the citing paper
“explaining preferential binding of IKZF1/IKZF3 to CRBN engaged with pomalidomide or lenalidomide over thalidomide in vitro (6), and the contribution of this residue to compound selectivity in vivo (fig. S5E).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [6]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Towards automated crystallographic structure refinement with phenix.refine
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H., & Adams, P. D. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912001308 · Cited by 5,511
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Cited by
Items 101–124 of 124
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion
List, A., Ebert, B. L., & Fenaux, P. (2018) · Leukemia · doi:10.1038/s41375-018-0029-9 · Cited by 49
Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders
Kroupova, A., Spiteri, V. A., Rutter, Z. J., Furihata, H., Darren, D., Ramachandran, S., Chakraborti, S., Haubrich, K., Pethe, J., Gonzales, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52871-9 · Cited by 47
“…mezigdomide and CRBN, no further interactions are observed between mezigdomide and IKZF1 ZF2 beyond the known stacking of the neo-substrate Gly-loop on top of the iso-indolinone ring, consistent with the molecular glue degrader binding exclusively to CRBN and not IKZF1 at the binary level 19,21 .”
BackgroundEladl, O. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117297 · Cited by 44
Shen, C., Nayak, A., Neitzel, L. R., Adams, A. A., Silver-Isenstadt, M., Sawyer, L. M., Benchabane, H., Wang, H., Bunnag, N., Li, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25634-z · Cited by 43
Bellail, A. C., Jin, H. R., Lo, H.-Y., Jung, S. H., Hamdouchi, C., Kim, D., Higgins, R. K., Blanck, M., le Sage, C., Cross, B. C. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1486 · Cited by 42
“Acknowledgments: We thank F. Melchior, R. T. Hay, and Z. J. Chen for providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-Ub-K48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT, and pEF-IRES-P-HA-R48.”
Cippitelli, M., Stabile, H., Kosta, A., Petillo, S., Gismondi, A., Santoni, A., & Fionda, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031103 · Cited by 42
“Indeed, although Ikaros and Aiolos are relevant common targets of all these drugs, only lenalidomide induces the degradation of the serine/threonine kinase CK1α [83], while CC-885 also triggers the depletion of the translation termination factor GSPT1 [81].”
BackgroundTateno, S., Iida, M., Fujii, S., Suwa, T., Katayama, M., Tokuyama, H., Yamamoto, J., Ito, T., Sakamoto, S., Handa, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61027-w · Cited by 36
Molecular glue degraders: exciting opportunities for novel drug discovery
Lemaitre, T., Cornu, M., Schwalen, F., Since, M., Kieffer, C., & Voisin-Chiret, A. S. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2306845 · Cited by 36
“The phthalimide (of thalidomide and pomalidomide) or isoin-dolinone (of lenalidomide) ring is exposed on the surface of the CRBN protein and alters the surface of the E3 ligase which is essential to interact with neosubstrates [23,32,33].”
BackgroundA small-molecule VHL molecular glue degrader for cysteine dioxygenase 1
Tutter, A., Buckley, D., Golosov, A. A., Ma, X., Shu, W., McKay, D. J. J., Darsigny, V., Dovala, D., Beckwith, R., Solomon, J., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01936-x · Cited by 36
Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
Steger, M., Nishiguchi, G., Wu, Q., Schwalb, B., Shashikadze, B., McGowan, K., Actis, M., Aggarwal, A., Shi, Z., Price, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62829-0 · Cited by 32
Patil, A., Manzano, M., & Gottwein, E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019031732 · Cited by 29
Selective and Potent Molecular Glue Degraders for NIMA‐Related Kinase 7
Chen, L., Huang, L., Wen, W., Zeng, P., Wu, Y., Han, Q., Chen, X., Guo, Z., Yu, H., Lu, W., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202500169 · Cited by 24
A cereblon-based glue degrader of NEK7 regulates NLRP3 inflammasome in a context-dependent manner
Sylvain, A., Stoehr, N., Ma, F., Cernijenko, A., Schröder, M., Khoshouei, M., Vogelsanger, M., Schoenboerner, M., Burke, A., Rao, P., et al. (2025) · Cell Chemical Biology · doi:10.1016/j.chembiol.2025.06.005 · Cited by 23
Ma, X., Leon, B., Ornelas, E., Dovala, D., Tandeske, L., Luu, C., Pardee, G., Widger, S., Solomon, J. M., Beckwith, R. E. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48606-3 · Cited by 21
Identification of an allosteric site on the E3 ligase adapter cereblon
Dippon, V. N., Rizvi, Z., Choudhry, A. E., Chung, C.-W., Alkuraya, I. F., Xu, W., Tao, X. B., Jurewicz, A. J., Schneck, J. L., Chen, W., et al. (2026) · Nature · doi:10.1038/s41586-025-09994-w · Cited by 14
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 9
“…as additional neo-substrates were discovered, such as cK1α, gSPt1, and p63, it was hypothesized that cRBN might not recognize a sequence-specific motif as these new substrates lacked the zinc-finger consensus sequence (Matyskiela et al. 2016; Petzold et al. 2016; Asatsuma-Okumura et al. 2019).”
InfluentialDiscovery of molecular glues that bind FKBP12 and novel targets using DNA-barcoded libraries
Zandi, T. A., Romanowski, M. J., Viscomi, J. S., Tan, Z. Y., Tong, B., Bonazzi, S., Zécri, F. J., Schreiber, S. L., & Michaud, G. A. (2024) · doi:10.1101/2024.12.09.627499 · Cited by 10
Structural mechanism of CRL4‐instructed STAT2 degradation via a novel cytomegaloviral DCAF receptor
Le‐Trilling, V. T. K., Banchenko, S., Paydar, D., Leipe, P. M., Binting, L., Lauer, S., Graziadei, A., Klingen, R., Gotthold, C., Bürger, J., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022112351 · Cited by 10
Cereblon induces G3BP2 neosubstrate degradation using molecular surface mimicry
Annunziato, S., Quan, C., Donckele, E. J., Lamberto, I., Bunker, R. D., Zlotosch, M., Schwander, L., Murthy, A., Wiedmer, L., Staehly, C., et al. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-025-01738-8 · Cited by 9
Self-citationBarankiewicz, J., Szumera-Ciećkiewicz, A., Salomon-Perzyński, A., Wieszczy, P., Malenda, A., Garbicz, F., Prochorec-Sobieszek, M., Misiewicz-Krzemińska, I., Juszczyński, P., & Lech-Marańda, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122683 · Cited by 7
Casein Kinase 1α—A Target for Prostate Cancer Therapy?
Lishman-Walker, E., & Coffey, K. (2024) · Cancers · doi:10.3390/cancers16132436 · Cited by 4
“The crystal structure of mammalian CK1 α when bound to small molecules has been resolved using X-ray diffraction, which will assist in the design of targeted agents [13,14].”
BackgroundCheng, C., Sun, L., Yang, J., Liu, Z., Zhang, F., Qiu, L., Yu, M., Wang, T., Huang, J., Wang, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73682-0
Scalable insect cell expression and purification screening applied to CRL4-DCAF substrate receptors
(2026) · doi:10.1016/j.pep.2026.106907
Metadata
- Authors
- Petzold, G., Fischer, E. S., & Thomä, N. H.
- Affiliations
- University of Basel (CH)
- Corresponding author
- Thomä, Nicolas H.
- Venue
- Nature
- Published
- 2016-02-24
- Volume
- 532
- Issue
- 7597
- Pages
- 127-130
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2283442479
- Semantic Scholar
- 0b70b452d7592d6f77195d47c938eb3d390e3942
- Cited by
- 620
- References
- 41
- Citations by year
- 2026: 77 · 2025: 84 · 2024: 80 · 2023: 62 · 2022: 56 · 2021: 64 · 2020: 63 · 2019: 49 · 2018: 40 · 2017: 33 · 2016: 10
- FWCI
- 23.05
- Type
- journal article
- Language
- en
- Open access
- green
- zenodo.org
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Keywords
- lenalidomide, CK1α, Ikaros, IKZF1, IKZF3, cereblon, thalidomide derivatives, protein degradation, ubiquitination, protein-protein interaction, multiple myeloma, hematologic malignancies, protein structure, drug repurposing
- MeSH terms
- Lenalidomide, Binding Sites, Humans, Models, Molecular, Protein Binding, Structure-Activity Relationship, Substrate Specificity, Thalidomide, Crystallography, X-Ray, Catalytic Domain, Ubiquitin-Protein Ligases, Casein Kinase Ialpha, Ikaros Transcription Factor, Ubiquitination, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.